|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 203.5 GBX | +3.83% |
|
-18.60% | -33.28% |
| 05-20 | Faron Pharmaceuticals’ Blood Cancer Combo Shows Efficacy in Mid-stage Study | MT |
| 05-20 | Faron Pharma celebrates positive read-out in ongoing MDS trial | AN |
Sept 21 (Reuters) - Faron Pharmaceuticals Oy:
* FARON PHARMACEUTICALS OY - APPOINTS DR. BIRGE BERNS, MD AS INTERIM CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:
| 1st Jan change | Capi. | |
|---|---|---|
| -33.28% | 179M | |
| +10.79% | 116B | |
| +11.65% | 106B | |
| -6.20% | 23.89B | |
| -3.17% | 21.58B | |
| -11.04% | 18.96B | |
| -13.41% | 16.33B | |
| -40.50% | 16.96B | |
| +6.64% | 14.14B | |
| +31.84% | 12.02B |
FARON PHARMACEUTICALS OY 
